Bavarian Nordic eyes external partnerships in bid to produce tens of millions of mpox vaccine doses

As mpox continues to cause illness and claim lives in Africa, Bavarian Nordic is retooling certain vaccine supply pacts to ensure its vaccine goes to the regions that need it most.

At the same time, the company is exploring options to dramatically boost the supply of Jynneos over the next 18 months.